Literature DB >> 15220676

Probiotics: a potential target for the prevention and treatment of steatohepatitis.

Gerardo Nardone1, Alba Rocco.   

Abstract

The accumulation of fat in hepatocytes with a necroinflammatory component-steatohepatitis-that may or may not have associated fibrosis is becoming a frequent lesion. Although steatohepatitis is currently recognized to be a leading cause of cryptogenic cirrhosis, the pathogenesis has not been fully elucidated. Among the various factors implicated, intestinal bacterial overgrowth may play a role. Indeed, various rat models of intestinal bacterial overgrowth have been associated with liver lesions similar to NASH, and bacterial overgrowth has been observed significantly more often in patients with NASH compared with control subjects. The authors discuss the relationship among intestinal bacterial overgrowth, steatohepatitis development, and probiotic treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220676     DOI: 10.1097/01.mcg.0000128934.53920.1d

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

1.  Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease.

Authors:  Farnush Bakhshimoghaddam; Mohammad Alizadeh
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 2.  Endotoxemia and gut barrier dysfunction in alcoholic liver disease.

Authors:  Radhakrishna Rao
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

3.  Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets.

Authors:  Fátima Higuera-de la Tijera; Alfredo I Servín-Caamaño
Journal:  World J Hepatol       Date:  2015-06-08

4.  The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis.

Authors:  Shudi Li; Jiangkai Liu; Zhen Wang; Fei Duan; Zi Jia; Xinju Chen; Suling Li
Journal:  Front Public Health       Date:  2022-07-25

5.  Focus on therapeutic strategies of nonalcoholic Fatty liver disease.

Authors:  Marilena Durazzo; Paola Belci; Alessandro Collo; Enrica Grisoglio; Simona Bo
Journal:  Int J Hepatol       Date:  2012-11-08

Review 6.  Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents.

Authors:  Ali Hashemi Kani; Seyed Moayed Alavian; Fahimeh Haghighatdoost; Leila Azadbakht
Journal:  Hepat Mon       Date:  2014-02-17       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.